Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges
April 28 2021 - 8:17AM
Business Wire
Foundation offers COVID-19 testing and support
to more than 2.1 million students as part of campus health
services
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, has partnered with the
Foundation for California Community Colleges to make COVID-19
testing available to the 116 California community colleges and
their more than 2.1 million students.
Through the Foundation’s CollegeBuys program, Biocept’s
PCR-based COVID-19 test is now available for community colleges to
purchase for students, faculty and staff. Access to and
availability of testing will provide information needed to help
protect the safety of campus populations and reduce the spread of
the virus on campuses and in surrounding communities if/when
colleges return from the current remote learning environment as a
result of the COVID-19 pandemic.
“As colleges prepare for in-person instruction, COVID-19 testing
is going to be critically important in keeping campuses and
students healthy and safe,” said Michael Nall, President and CEO of
Biocept. “We are proud to leverage our molecular testing
capabilities to support California’s community colleges and their
students, faculty and staff during these unprecedented times.”
“Expanding access to COVID-19 testing supplies is essential to
smart and safe reopening strategies for the California Community
Colleges—safeguarding the health and wellness of our students,
faculty and staff,” said Jorge J.C. Sales, Vice President of
Program Development at the Foundation for California Community
Colleges.
Biocept will provide colleges with PCR-based COVID-19 testing,
which detects the genetic information of the virus, through its
CLIA-certified, CAP-accredited San Diego laboratory. The assay
detects the presence of SARS-CoV-2 and is intended for use with
patients who meet current guidance for evaluation of infection with
COVID-19. The test is administered by a health care provider using
a nasal or oral swab, and most results will be available within 48
hours of Biocept’s receipt of the sample, reducing lengthy
turnaround times.
This partnership and the access to COVID-19 testing for the
colleges are made possible through the Foundation’s CollegeBuys
program, the systemwide procurement vehicle which leverages the
purchasing power of the 116 colleges to offer a number of services
and products at up to 85% discount, ensuring colleges can meet the
educational needs of students.
About the Foundation for California Community Colleges
The Foundation for California Community Colleges is the official
nonprofit foundation to the California Community Colleges Board of
Governors and Chancellor's Office. The Foundation's mission is to
benefit, support, and enhance the missions of the California
Community Colleges system, the largest higher education system in
the nation. Incorporated in 1998, the Foundation works to benefit
all California Community College students, colleges, college
foundations, and the system as a whole by accelerating paths to
economic and social mobility, strengthening communities, and
reducing barriers to opportunities for all Californians. The
Foundation is a 501(c)(3) tax-exempt non-profit organization. For
more information, visit www.foundationccc.org.
About CollegeBuys CollegeBuys is the Foundation’s
systemwide procurement vehicle that leverages the buying power of
California’s 116 community colleges to offer discounts of up to 85
percent on a wide range of educational products—from
industry-leading software and technology to high quality office and
classroom furniture. For more information, visit
www.collegebuys.org.
About Biocept Biocept, Inc. develops and commercializes
molecular diagnostic assays that provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with a variety of cancers. In addition to its broad
portfolio of blood-based liquid biopsy assays, Biocept has
developed the CNSide™ cerebrospinal fluid assay that detects cancer
that has metastasized to the central nervous system. Biocept’s
patented Target Selector™ technology captures and quantitatively
analyzes CSF tumor cells for tumor-associated molecular markers,
using technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding our ability to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with a variety of cancers, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210428005228/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301 Investor Contact:
Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024